Free tool
Find any stock
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
15 stocks in Europe match these filters · market cap, largest first. Clear filters
Data as of Aug 27, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | Price | vs 52-week high | 1M return |
|---|---|---|---|---|---|---|
| 0L35.L | Sarepta Therapeutics, Inc. | Rare disease | $1.69B | $18.51 | −26.95% | +1.60% |
| 0LIF.L | Ultragenyx Pharmaceutical Inc. | Rare disease | $1.40B | $26.19 | −36.89% | +1.39% |
| 0HB0.L | Agios Pharmaceuticals, Inc. | Rare disease | $1.19B | $34.05 | −25.68% | +0.18% |
| DBV.PA | DBV Technologies S.A. |
Every company we cover sits in at least one of these lists. Each one opens as a full table of its members, ordered by market value.
The 11 business sectors every covered company is classified into.
The 20 narrower groupings we keep for parts of the market that do not split neatly by sector.
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock, $9.90 each. Already know the symbol?
| Rare disease |
| $901.25M |
| 2.53 EUR |
| −43.78% |
| +5.42% |
| GNFT.PA | Genfit S.A. | Rare disease | $830.56M | 14.30 EUR | −5.92% | +5.30% |
| 0QNA.L | Basilea Pharmaceutica AG | Rare disease | $762.45M | 65.80 CHF | −1.05% | +2.73% |
| AYJ.DE | Valneva SE | Rare disease | $619.77M | 2.98 EUR | −43.20% | +35.29% |
| 0KBU.L | Omeros Corporation | Rare disease | $575.28M | $18.44 | −5.99% | −4.75% |
| 0OB3.L | Valneva SE | Rare disease | $270.41M | 2.87 EUR | −46.23% | +0.75% |
| XUP.DE | Genfit S.A. | Rare disease | $258.22M | 14.08 EUR | −1.81% | −1.81% |
| 0QN1.L | Santhera Pharmaceuticals Holding AG | Rare disease | $254.58M | 15.66 CHF | −16.35% | −1.88% |
| 0T6G.L | Q32 Bio Inc. | Rare disease | $246.69M | $16.34 | −30.47% | +7.94% |
| 0AB6.L | Hyloris Pharmaceuticals SA | Rare disease | $185.32M | 4.38 EUR | −46.72% | −1.79% |
| CRNO-B.ST | Cereno Scientific AB (publ) | Rare disease | $148.23M | 4.71 SEK | −57.60% | +0.13% |
| 0H8T.L | Aclaris Therapeutics, Inc. | Rare disease | $122.82M | $6.14 | −6.69% | −6.69% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.
Size bands, from the largest companies down to the smallest we cover.
The 23 listing venues our coverage spans, across the Americas, Europe and Asia-Pacific.
5 lists built on a single stated criterion, such as paying a dividend or trading near a 52-week high.
The largest one day percentage moves in either direction, among the mid, large and mega cap companies we cover.